DelveInsight’s “Minimal Residual Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Minimal Residual Disease, historical and forecasted epidemiology as well as the Minimal Residual Disease therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Unlock key insights into the Minimal Residual Disease Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Minimal Residual Disease Market Size

Key Takeaways from the Minimal Residual Disease Market Report

• In April 2025, Janssen Research & Development LLC announced a study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance treatment to anti-cluster of differentiation 38 (CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD positive as determined by next generation sequencing (NGS) at screening, following high-dose therapy (HDT) and autologous stem cell transplant (ASCT).
• In April 2025, Pfizer conducted a study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years.
• According to the statistics published by the American Cancer Society 2022, 34,470 new cases of multiple myeloma in the United States in 2022.
• About 6,660 new cases of acute lymphocytic leukemia (ALL) in 2022.
• As per the statistics published by the Leukemia and Lymphoma Society, in 2021, 90,390 new lymphoma cases were expected to be diagnosed in patients in the United States, of which 8,830 cases would be of Hodgkin lymphoma and 81,560 cases of non-Hodgkin lymphoma.
• The leading Minimal Residual Disease Companies such as Adaptive Biotechnologies, Foresight Diagnostics, Cergentis B.V., ICON plc, 3B BlacBio Biotech, EntroGen, Quest Diagnostics, ImmuQuad, Foresight Diagnostics, Cergentis B.V., Natera, Invivoscribe Inc., Idylla Technology, and others
• Prominent Minimal Residual Disease Therapies such as ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR® PML-RARA, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, Signatera, LymphoTrack, Biocartis, and others.

Stay ahead in the competitive landscape of the Minimal Residual Disease Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Minimal Residual Disease Treatment Market Size

Minimal Residual Disease Epidemiology Segmentation in the 7MM

• Total Minimal Residual Disease testing
• Total Minimal Residual Disease cases by cancer type
• Total Minimal Residual Disease testing from different blood cancers
• Total Minimal Residual Disease testing for HSCT-related transplant
• Total Minimal Residual Disease testing during new therapy and maintenance therapy
• Total number of Minimal Residual Disease Testing by age

Download the report to understand which factors are driving Minimal Residual Disease Epidemiology trends @ Minimal Residual Disease Prevalence

Minimal Residual Disease Market Dynamics

The dynamics of the minimal residual disease market is expected to change in the coming years. Several organizations and companies, including the European Scientific Foundation for Laboratory Hemato Oncology (ESLHO), the Leukemia and Lymphoma Society (LLS), and European LeukemiaNet (ELN), are raising awareness about the disease, which may result in a larger patient pool. Moreover, recent advances in high-throughput molecular genetics technologies, such as next-generation sequencing (NGS), may now provide a novel approach to detecting MRD.

Minimal Residual Disease Therapies and Companies

• ClonoSEQ: Adaptive Biotechnologies
• PhasED-Seq: Foresight Diagnostics
• Targeted Locus Amplification (TLA) technology: Cergentis B.V.
• MRDx BCR-ABL Test: ICON plc
• TRUPCR® PML-RARA: 3B BlacBio Biotech
• Signatera: Natera
• Leukemia Fusion Gene One-Step Detection Kits: EntroGen
• CBFB/MYH11 inv(16): Quest Diagnostics
• Seq-MRD: ImmuQuad
• PhasED-Seq: Foresight Diagnostics
• Targeted Locus Amplification (TLA) technology: Cergentis B.V.
• TRUPCR® PML-RARA: 3B BlacBio Biotech
• CBFB/MYH11 inv(16): Quest Diagnostics
• LymphoTrack: Invivoscribe Inc.
• Biocartis: Idylla Technology

Discover the future of Minimal Residual Disease Treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ Minimal Residual Disease Market Drivers and Barriers

Scope of the Minimal Residual Disease Market Report

• Coverage- 7MM
• Study Period- 2019-2032
• Minimal Residual Disease Companies- Adaptive Biotechnologies, Foresight Diagnostics, Cergentis B.V., ICON plc, 3B BlacBio Biotech, EntroGen, Quest Diagnostics, ImmuQuad, Foresight Diagnostics, Cergentis B.V., Natera, Invivoscribe Inc., Idylla Technology, and others
• Minimal Residual Disease Therapies- ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR® PML-RARA, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, Signatera, LymphoTrack, Biocartis, and others.
• Minimal Residual Disease Market Dynamics: Minimal Residual Disease Market Drivers and Barriers
• Minimal Residual Disease Market Access and Reimbursement, Unmet Needs and Future Perspectives

Explore the dynamics of the Minimal Residual Disease Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Minimal Residual Disease Ongoing Clinical Trials Analysis

Table of Content

1. Key Insights

2. Executive Summary of Minimal Residual Disease

3. Competitive Intelligence Analysis for Minimal Residual Disease

4. Minimal Residual Disease: Market Overview at a Glance

5. Minimal Residual Disease: Disease Background and Overview

6. Minimal Residual Disease Patient Journey

7. Minimal Residual Disease Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Minimal Residual Disease Unmet Needs

10. Key Endpoints of Minimal Residual Disease Treatment

11. Minimal Residual Disease Marketed Products

12. Minimal Residual Disease Emerging Therapies

13. Minimal Residual Disease: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Minimal Residual Disease Market Outlook

16. Access and Reimbursement Overview of Minimal Residual Disease

17. KOL Views

18. Minimal Residual Disease Market Drivers

19. Minimal Residual Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/minimal-residual-disease-market